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Abstract
Diabetes mellitus (DM) could cause pilot incapacitation and result in aviation fatalities. The mechanisms could be directly as a
consequence of acute hypoglycemia/subacute diabetic ketoacidosis (DKA) or indirectly as an acute cardiovascular event by
contributing to the development of atherosclerosis in coronary or carotid and cerebral arteries. In this study, DM-related fatal
flight accidents in the US National Transport Bureau’s database between years 2011–2016 were analyzed with special emphasis
on postmortem (PM) glucose levels and correlation of toxicological reports with anamnestic information on DM. Additionally,
autopsy results on coronary arteries were reviewed. In 43 out of 1491 (~ 3%) fatal accidents pilots had DM. Postmortem glucose
or glycated hemoglobin percentage (Hb1Ac) was measured in 12 of the 43 cases; while antidiabetic medication was found in 14
of the cases (only two of the cases had both glucose measurements and medication). With the increasing prevalence of DM, a
possibility of pilot incapacitation due to DM or complications of DM should be actively studied, even if no anamnestic
information of DM was available. While PM hypoglycemia is difficult to assess, we propose a systematic investigation based
on measurement of glucose, Hb1Ac%, and ketone bodies, and documentation of atherosclerotic lesions in major arteries to
identify or rule out DM as a cause of pilot incapacitation.
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Roughly 30.3 million adults in the USA have diabetes (diabe-
tes mellitus, DM) and the overall prevalence of DM is 9.4%.
Strikingly, of these individuals, 7.2 million are not aware they
have DM (~ 24% of all diabetics) (http://www.diabetes.org/
diabetes-basics/statistics/). In aviation, DM does not
necessarily prevent a pilot from obtaining a license to fly. In
the UK, the UK Civil Aviation Authority (CAA) may permit,
according to recent practice, a class I medical certificate (re-
quired for all pilots involved in commercial aviation) to com-
mercial pilots with type I DM upon careful monitoring of
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blood glucose level [1]. In contrast in the USA, insulin-treated
DM remains an absolute disqualifying condition for obtaining
a class I medical certificate; however, private pilots may ob-
tain a specific waiver to obtain a certificate to fly [2]. As for
aviation safety, since ~ 24% of people with DM are unaware
of their disease (http://www.diabetes.org/diabetes-basics/
statistics/), screening of pilots for undiagnosed DM should
be a requisite. The screening necessity is of particular
importance given an increasing aging of the general
population (note that prevalence of DM in individuals
65 years and older is 25.2%; http://www.diabetes.org/
diabetes-basics/statistics/) and that in the USA currently only
very limited checkups for aging pilots are required [3].
Pilot incapacitation due to DM-related causes may occur
gradually or suddenly. Typical forms of sudden incapacitation
are hypoglycemia, in which loss of consciousness is due to
lack of glucose in the central nervous system (CNS) [4] and
ischemia-induced cardiac arrhythmias. Furthermore, DM-
associated hypoglycemia can subject a person to cardiac ar-
rhythmias, especially with type 2 diabetes (DM2) [5]. DM
also increases the risk of cardiovascular disease two- to five-
fold [6], which increases the risk of a pilot to become suddenly
incapacitated due to acute myocardial infarction (AMI) or
cardiac arrhythmia induced by AMI. In addition to coronary
atherosclerosis being more common in diabetic individuals,
the prognosis of diabetics with coronary atherosclerosis is
poorer than in non-diabetics [7, 8]. In fact, a person with
diagnosed DM2 without previous AMI has a similar risk of
developing AMI than a non-diabetic with previous AMI [9].
Finally, DM also directly increases the risk of a stroke [10].
Incapacitation may also occur gradually due to hypergly-
cemia. In hyperglycemia, incapacitation occurs via glucagon
induction and subsequent rise in blood glucose level, as well
as fatty acid release from adipose tissue. If glucose balance is
not corrected, this process eventually leads to diabetic
ketoacidosis (DKA). Sudden pilot incapacitation due to hypo-
glycemia is difficult to demonstrate, since reliable blood glu-
cose level or insulin measurement postmortem (PM) is chal-
lenging; but gradual incapacitation caused by DKA can be
readily addressed [11].
Hypoglycemia, as a possible cause of pilot incapacitation,
is considered in flight accidents involving pilots with DM, but
the task is hampered by rapid depletion of glucose (and insu-
lin) PM [12]. A pilot’s medical history available for accident
investigators is often incomplete, but by combining data from
a pilot’s medical records and PM toxicological and biochem-
ical analyses estimations can be made of the short- and long-
term glucose balance of DM treatment prior to an accident. In
aviation fatalities biochemical PM investigation should in-
clude the analysis of long-term blood glucose balance (per
cent of glycated hemoglobin, HbA1c) as well as urine and
vitreous glucose levels [12–14]. New tools for investigating
DM-related pH imbalance, for example ketone bodies, have
also been added to PM investigations [11, 15], while on the
basis of methodological development [16] and systematic case
evaluation adding HbA1c measurement into all routine PM
evaluations of carbohydrate metabolism disturbance was re-
cently suggested [16].
In this study, we analyze how DM was addressed in fatal
flight accident final reports in the USA between 2011 and
2016 to better understand the challenges posed by DM-
related conditions (hypoglycemia, hyperglycemia, DKA, and
microvascular diseases).
Materials and methods
Systematic analysis of fatal flight accidents in the USA be-
tween 1/1/2011–14/7/2017 with DM as an underlining factor
for the incidents was performed on August 15, 2017 in the
National Transportation Safety Board Aviation (NTSB) data-
base (https://www.ntsb.gov/_layouts/ntsb.aviation/index.
aspx). The search word used was Bdiabetes^. The search
returned 45 cases of 1491 fatal flight accidents during this
period, of which 2 were not linked to DM (one case
included discussion on management of DM after stroke and
the other one discussed treatment of diabetes insipidus). PM
reports were reviewed with special focus on analysis of body
fluid glucose and/or HbA1c as a read-out for imbalance of
DM treatment. In addition, whether DM was reported to the
Federal Aviation Administration (FAA) in the latest aeromed-
ical assessment(s) before the accident flight was assessed.
Results
Anamnestic evidence of DM in the accident reports
Of the 43 cases identified, FAA was informed in 18 (42%)
cases that the pilot had DM, and in the latest aeromedical
assessment, 17 (40%) of the cases DM were not reported. In
the remaining eight (19%) cases, it was unclear if FAA was
aware of pilots’ DM (Table 1) (N.B. the percent of cases,
42% + 40% + 19%, is 101% due to the percent round up of
numbers). Interestingly, in 37 (86%) cases, there was
Table 1 Anamnestic knowledge of DM diagnosis of pilots by primary
health care (GP) or FAA in 43 fatal flight accidents involving pilots with
DM in the USA between 2011 and 2016. (N.B. the percent of cases,
42% + 40% + 19%, is 101% due to the percent round up of numbers)
Knowledge of DM GP no. of cases (%) FAA no. of cases (%)
Informed 37 (86) 18 (42)
Not informed 2 (5) 17 (40)
Not known 4 (9) 8 (19)
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indication that the general practitioner (GP) or primary care
doctor was aware of the DM diagnosis, in four (9%) cases, it
was unclear if the primary health care provider was aware of
the DM and in two cases, the primary care doctor was not
aware of the DM diagnosis.
Postmortem laboratory data
Toxicology reports
The toxicology reports of the accident investigation reports
were reviewed with special emphasis on evidence of DM. In
14 (33%) of the 43 cases, PM toxicology provided evidence of
DM, i.e., glipizide alone (n = 5), pioglitazone alone (n = 5),
glyburide (n = 1), sitagliptin (n = 2), combination of glipizide
and pioglitazone (n = 1). The general characteristics of the
accidents in these 14 cases are shown in Table 2. Of these
14 cases, diagnosis of DM was reported to FAA in 9 cases,
in 3 cases, known DM was not reported and in 2 cases, it was
unclear whether FAAwas notified of the pilots’ DM.
The toxicology reports indicated that many of the pilots
used other personal medications, and in some cases, they used
illicit drugs or medications not allowed in flying. For other
PM toxicological analysis, carbon monoxide (CO) was ana-
lyzed in 15 cases (all cases were negative) and not analyzed in
28 cases. Ethanol was analyzed in 27 cases (20 negative). Six
postmortem toxicology tests for ethanol were positive, but in
these cases, ethanol was from sources other than ingestion. In
one case, it was impossible to deduce whether the ethanol was
from ingestion or other sources. Of the 16 cases where ethanol
was not analyzed PM, seven cases had elevated PM glucose
values. In addition, five of these 16 cases had antidiabetic
medication in PM toxicology.
Glucose analysis
Since PM glucose level analysis in urine samples has been in
routine use in aviation accident investigations in the USA
since 1998 or for long-term glucose balance analysis
(HbA1c) since mid-2001 [17], the accident investigation final
reports between 2011 and 2016 were reviewed to analyze how
systematic was PM evaluation of glucose balance (Table 3).
Quantitative information on any type of glucose information
(vitreous, blood, urine) was reported in only 11 cases; in one
report urine glucose was Bdetected^ but not quantitated.
Average percent of blood HbA1c (n = 9) was 7.9% (4.8–
10.3%), average urine glucose (n = 11) was 1271 mg/dl (12–
3000 mg/dl) and average vitreous glucose (n = 8) was 42 mg/
dl (0–149 mg/dl). No information on possible ketone body
measurements was available. Two hundred thirty-four milli-
gram per deciliter [18] or 180 mg/dl [19] have been suggested
as cutoff values for fatal antemortem (AM) hyperglycemia in
vitreous fluid. Practically, any trace of glucose in the vitreous
fluid is likely an indication of antermortem hyperglycemia
[20]. For urine PM glucose measurements, specifying cutoff
values for evaluating AM glucose balance from PM urine
samples is challenging, and the urine glucose measurement
should primarily be used to confirm vitreous findings [21–23].
Discussion
Between 2011 and 2016, 43 flight accidents related to DM in
the USAwere discovered in the NTSB aviation database (out
of 1491 accidents; ~ 3%). As a reference, Chaturvedi et al.
performed a search of elevated vitreous and/or urine glucose
in fatal flight accidents between 1998 and 2005 in the USA for
2487 deceased pilots, and they found 43 had elevated glucose
Table 2 Summary of
postmortem-identified antidiabet-
ic medications of pilots in DM
diabetes-related fatal flight acci-
dents in the USA between 2011
and 2016. Altogether, 43 acci-
dents were found; in 14 cases,
postmortem toxicology of the pi-
lots was positive for antidiabetic
medication. Number of lives lost
in these accidents is indicated.M,
male; No, number
DM medication in toxicology Pilot age, sex, and accident year No. of lost lives in the accident
Glipizide 60 M, 2011 1
65 M, 2011 1
56 M, 2012 1
69 M, 2012 1
68 M, 2016 1
Pioglitazone 53 M, 2011 1
63 M 2012 1
62 M, 2012 1
74 M, 2013 1
44 M, 2013 2
Glyburide 73 M, 2014 1
Sitagliptin 63 M, 2015* 2
56 M, 2016 1
Glipizide + pioglitazone 79 M, 2012** 1
*flight student, **flight instrutor
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levels (1.7%) [17]. Altogether, 58 lives were lost in the
reviewed accidents here; the mean age of pilots (all male)
was 62.4 (range 28–83 years), the median age was 63 years.
In addition, in these accidents eight persons were severely
injured, and one person suffered minor injuries. In 25 cases,
health-related issues were not indicated as affecting the acci-
dent according to the accident final report; while in 18 cases,
health of the pilot was either contributing to the accident or it
was not possible to rule out that a health issue contributed to
the accident. Autopsies revealed that in nine cases, the pilots
had coronary atherosclerosis. In cases, where coronary athero-
sclerotic occlusion (%) was indicated in the autopsy report
(n = 7), the area of coronary artery occlusion was > 75%. In
other cases, the occlusion was indicated by description as
Bsevere^ (n = 1) or Bmild^ (n = 1). In six additional cases,
atherosclerosis was present, but either its severity was not
reported in the autopsy or the information was based on med-
ical records.
Fatal flight accidents are investigated with a standardized
protocol (ICAO annex 13) [24]. The protocol aims at investi-
gating all contributory explanations for the accident and to
identify the actual cause for an accident so that future acci-
dents may be prevented. The medical condition of a pilot is
always a critical part of such an investigation. With the in-
creasing incidence of DM2, its role as a possible cause or
contributing factor in an accident needs to be considered. In
2013, global prevalence of DM (both DM1 and DM2) was
estimated to be 382 million people and in 2035, it is estimated
to be 592 million people, with DM2 representing ~ 85% of all
DM cases [25]. Both the risk for AMI and for stroke are
elevated in diabetic individuals [6, 9, 10]. In addition, older
individuals with DM are at substantial risk of acute cardiovas-
cular complications [26], which underlines the importance of
health reviews of aging pilots especially those with DM.
The role of insulin-treated DM is relatively low as a cause
of accidents involving pilots carrying a third-class medical
certificate, a certificate required to obtain a private pilot li-
cense in the USA [2]. This estimation is based on the analysis
of 1500 waivers for insulin-treated DM approved by FAA,
which did not indicate increased risk for fatal accidents be-
tween 1997 and 2014 for pilots with DM [2]. The overall
accident rate for pilots with a waiver for insulin was 7.0 for
100,000 flight hours, while an estimate for all third-class pilots
was exactly the same (7.0/100000 flight hours) [2]. This find-
ing would suggest that insulin-treated DM may not add risk
for an accident. However, this conclusion may underestimate
the role of DM, due to the fact that hypoglycemia that might
affect the accident is difficult to address in PM diagnostics.
Interestingly, the prevalence of DM (DM1 and DM2) in the
USA is 9.4% (http://www.diabetes.org/diabetes-basics/
statistics/) while pilots with DM in fatal flight accidents in
the USA the prevalence was ~ 3%, which would also
suggest that DM was not increasing the risk for fatal
accidents since prevalence among diabetic pilots in accidents
is actually lower than DM in the general population. Various
explanations could account for this difference. First, the lack
of information flow of the pilots’DM to the aviation authority
(FAA) may result in an underestimation of the number of
diabetic pilots (Table 1) and thus could discourage the search
for DM in accident review. Retrospectively, in cases studied
herein, FAA was informed in only 43% of the cases that the
pilots had DM. Second, medical screening of pilots may re-
move diabetics withmore severe DM-related complications as
pilot candidates. Third, the medical screening (for Hb1Ac and
diabetic complications) combined with more regular doctor
visits for pilots with DM might select pilots with DM that
are overall more healthier than non-diabetic pilots. Fourth,
the difficulty in measuring postmortem hyperglycemia and
particularly hypoglycemia might underestimate the number
of diabetes-related accidents. Fifth, a combination of these
factors could be involved.
Table 3 Available postmortem
glucose metabolism
measurements from diabetes DM-
related flight accidents between
2011 and 2016 in the USA.
Where available, the source of the
blood sample for HbA1c mea-
surement is indicated in paren-
theses. N/A data not available, M
male, Blood source: C cavity, H
heart, F femoral artery
Pilot age, sex, and accident year Blood Hb1Ac % Urine glucose (mg/dl) Vitreous glucose (mg/dl)
63 M, 2011 4.8% (C) 3000 Not detected
63 M, 2012 N/A Detected Not detected
51 M, 2012 N/A 2460 N/A
79 M, 2012** 8.7% 1150 N/A
58 M, 2013 7.0% (H) 1949 149
58 M, 2013 9.2% (C) 484 N/A
51 M, 2013 10.3% (C) 1668 46
56 M, 2013 8.6%. (F) 2514 82
73 M, 2014 6.1% 12 N/A
47 M, 2014 N/A 248 51
57 M, 2014 7.4% 135 Not detected
80 M, 2015 9.0% 366 8
**flight instructor
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Interestingly, antidiabetic medication in the toxicology re-
ports and elevated glucose in the body fluids correlated only in
two cases. This could be due to a good balance of DM treat-
ment. Those individuals not using the DM medication (either
for not knowing they did have DM or for lack of compliance)
would have elevated glucose levels. However, it is also pos-
sible that antidiabetic medication subjects one to hypoglyce-
mia. Another common cause of hypoglycemia could be etha-
nol particularly combined with antidiabetic medication [27].
In this study, of the 16 cases where ethanol was not analyzed
PM, seven cases had elevated PM glucose values which
leaves open the theoretical possibility of ethanol-induced hy-
poglycemia in nine cases. One of these individuals with un-
clear ethanol status and antidiabetic medication had elevated
glucose levels PM. In four cases with antidiabetic medication,
PM without ethanol assessment hypoglycemia status remain
unknown, but possible.
In a diabetic individual glucose, HbA1c% and ketone
body levels are measured to determine the balance of DM
treatment. In clinics, blood (and urine) glucose levels can be
easily measured. However, when treating diabetic patients,
long-term glucose levels are important for patient evalua-
tion [28]. HbA1c% provides a reliable measure of blood
glucose level over a period of several weeks (4–8 weeks),
while it does not catch acute hypoglycemia. In clinics,
HbA1c measurement is usually combined with a measure-
ment of blood glucose level (either fasting or non-fasting) as
well as serum ketone bodies and acidosis (serum bicarbon-
ate) [4, 28]. In the routine postmortem investigation, DM as
a primary or underlining cause of death is difficult to diag-
nose due to lack of specific macroscopic and microscopic
findings. Also, PM glucose analysis is not feasible due to
rapid glucose metabolization (glycolysis) into lactate [21].
However, using the recently developed biochemical analy-
ses, and alternative matrices (such as vitreous humor and
urine), fatal DM-related ketoacidosis is readily diagnosed,
even in cases of no medical history of DM or cadavers with
advanced postmortem changes [22, 29, 30]. Recently
Palmiere discussed the caveats on using a single measure-
ment as a definitive indication of dysregulation of glucose
metabolism [31]; single measurement of glucose metabo-
lism from any PM sample is likely unreliable. HBA1c and
vitreous glucose measurements are used to assess glucose
balance. The measurement of urine glucose can be support-
ive of the results obtained in vitreous fluid but if the urine is
the only sample available, the significance of the measure-
ment results should be carefully estimated [12–14]. It is
clear that more sophisticated measurement tools of glucose
balance will help in analyzing AM glucose balance in post-
mortem analysis; one candidate approach could be 1,5-
anhydro-d-glucitol, which has shown promise in identify-
ing AM diabetic coma in postmortem analysis [32]. In the
USA, vitreous fluid and urine glucose analyses were
implemented as routine tests for flight accident investiga-
tions in the beginning of 1998, and blood HbA1c testing
was implemented in the middle of 2001 [17]. One difficulty
in assessing DM as a cause of pilot incapacitation in avia-
tion accidents is the high energy forces associated with the
accidents which make it difficult to obtain samples (body
fluids) for analysis. Another critical feature in PM investi-
gation related to DM is the status of coronary arteries and
major CNS-arteries in context of atherosclerosis as a com-
plication of DM. Finally, an accident investigation needs to
take into account what factor(s) medication(s) may play in
pilot incapacitation. Insulin and oral DM medication are a
risk factor for hypoglycemia, and other simultaneous med-
ications via various mechanisms may increase the hypogly-
cemic effect of oral DMmedication [33]. Thus, pilots’med-
ical records for prescriptive or over the counter medications,
as well as toxicological report findings, need to be reviewed
from the perspective of medication-induced hypoglycemia.
Recently, analysis of exogenous insulin has become possi-
ble from postmortem samples [30, 31, 34, 35] which can
also be added to aviation fatality investigation when hypo-
glycemia due to insulin use is suspected.
Multidrug use is a common finding in the realm of medi-
colegal autopsies [36, 37] and it is also challenge for fatal
aviation accident investigations, as well as to AMEs and pi-
lots’ general practitioners. In cases reviewed herein, the me-
dian age of pilots during the accident was 63. Recently, 13%
of US general aviation pilots over 70 years involved in a fatal
accident were shown to have used three or more medications
during the accident as indicated by the toxicology findings,
with antihistamines and antidepressants the most frequently
discovered substances [3].
Hypoglycemia, as a cause of sudden pilot incapacitation, is
currently practically nearly impossible to address.
Hyperglycemia and insulin deficiency-related DKA as cause
of gradual pilot incapacitation should be investigated more
extensively. Overall, given the high prevalence of DM, espe-
cially in the aging population, and the lack of disclosure of
DM to FAA indicated in the study herein, glucose measure-
ments, accompanied by measurement of ketone bodies (ace-
tone, acetoacetate, β-hydroxybutyrate), should be a part of a
standard investigation in an aviation fatality during the post-
mortem investigation of the pilot.
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